Cholinesterase
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cholinesterase as ChEMBL target CHEMBL5763, mapped to UniProt P81908. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Cholinesterase matters
Cholinesterase is reviewed as Cholinesterase (UniProt P81908); the current evidence base includes 34 approved drugs, 7437 compounds, and 857 assays, with lead potency reaching pChEMBL 10.7.
Cholinesterase Sequence length is 574 aa.
Review this target as Cholinesterase, mapped to UniProt P81908. Sequence length is 574 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 34 approved drugs, 7437 compounds, and 857 assays for this target. The dominant activity type is IC50. CHEMBL5201089 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL5201089 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Cholinesterase matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P81908, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5201089
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL2158116
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL5592238
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL5595714
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL5584158
|
10.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CANNABIDIOL
CHEMBL190461
|
2018 |
|
|
NEOSTIGMINE
CHEMBL278020
|
2013 |
|
|
RIVASTIGMINE
CHEMBL636
|
1998 |
|
|
RIVASTIGMINE TARTRATE
CHEMBL1201092
|
1998 |
|
|
DONEPEZIL
CHEMBL502
|
1996 |
|
|
TACRINE
CHEMBL95
|
1993 |
|
|
TACRINE HYDROCHLORIDE
CHEMBL1677
|
1993 |
|
|
SIMVASTATIN
CHEMBL1064
|
1991 |
|
|
ETHOPROPAZINE
CHEMBL1206
|
1982 |
|
|
DIAZEPAM
CHEMBL12
|
1963 |
|
|
CHLORDIAZEPOXIDE HYDROCHLORIDE
CHEMBL1200703
|
1960 |